Clinical and Epidemiological Study of Vitiligo Patients at a Dermatology Service in Northern Brazil
Background: Vitiligo is an acquired hypomelanosis that affects between 0.5% and 4% of the world population, characterized by distinct acromic macules of various shapes and sizes, and may appear in any region of the skin. Worldwide, there are few publications on vitiligo that address epidemiological characteristics. Thus, the objective was to describe the clinical and epidemiological profile of patients with this condition at the State University of Pará’s Dermatology Clinic, in the city of Belém, Northern of Brazil.
Methods and Findings: A cross-sectional descriptive study was performed, in which 180 medical records of patients treated at the State University of Pará’s Dermatology Clinic, from July 2000 to July 2014, were analyzed using a protocol consisting of variables related to the disease. The information obtained was organized in a database and submitted to descriptive and inferential statistical analysis. The study was approved by the ethics and research committee under the number 923.213. A predominance of the female gender (72.2%), of the adult age group (55%) was observed; without relation to family history (46.7%); without progression (58.3%); with a predominant clinical form of vitiligo of the generalized type (67.2%), being the common generalized one with the highest prevalence (57%). The most affected sites were head and neck (27.5%), and upper limbs (25.3%).
Conclusions: This study revealed the characteristics of the vitiligo patient residing in the Amazon region, and patients were found to have a generalized clinical form, most of the patients achieved improvement of the lesions with the proposed treatment, and only a minority presented progression of the disease. It is concluded that vitiligo is a disease with great therapeutic difficulty, and it is emphasized the importance of an early diagnosis, since in the early stages is easier to resolve the disease.
2. Marinho Fde S, Cirino PV, Fernandes NC. Clinical epidemiological profile of vitiligo in children and adolescents. An Bras Dermatol. 2013 Nov-Dec; 88(6):1026-28.
3. Neto ATM, Silva VS, Rodrigues MD, Pinto FO. Vitiligo: o problema que não está apenas na pele. Reinpec. 2015 Jul-Dez;1:250-267.
4. Tarlé RG, Nascimento LM, Mira MT, Castro CC. Vitiligo – Part 1. An Bras Dermatol. 2014 May-Jun;89(3):461-70
5. Pernas GA. Factores pronósticos en el vitíligo. Rev Cub Invest Biomed. 2014;33(3):289-293.
6. Nunes DH, Esser LM. Vitiligo epidemiological profile and the association with thyroid disease. An Bras Dermatol. 2011; 86(2):241-8.
7. Luz LL, Santos SL, Partata A. Vitiligo e seu tratamento. Rev Cient do ITPAC. 2014;7:3.
8. Faria AR, Tarlé RG, Dellatorre G, Mira MT, Castro CCS. Vitiligo – Part 2: classification, histopathology and treatment. An Bras Dermatol. 2014; 89(5):784-90.
9. Vizani RO, Maia FSM, Vasconcelos TP, Pimentel SLG, Yuri V, Silva VNE, Kashiwabara TGB. O vitiligo: uma doença orgânica e psíquica. BJSCR. 2014 Mar-Mai;6(3):47-52.
10. Andrade D, Ferraz RRN, Coelho AB, Pinto JM. Avaliação do paciente com vitiligo frente as representações sociais acerca da doença. Ruep. 2016 Abr-Jun;13:58-62.
11. Ayres M et al. Aplicações Estatísticas nas Áreas das Ciências Biológicas e Médicas. 5. ed. Belém-PA: Publicações Avulsas do Mamirauá; 2007.
12. de Barros JC, Machado Filho CD, Abreu LC, de Barros JA, Paschoal FM, Nomura MT et al. A study of clinical profiles of vitiligo in different ages: an analysis of 669 outpatients. Int J Dermatol. 2014 Jul;53(7):842-8.
13. Tejada Cdos S, Mendoza-Sassi RA, Almeida HL Jr, Figueiredo PN, Tejada VF. Impact on the quality of life of dermatological patients in southern Brazil. An Bras Dermatol. 2011 Nov-Dec;86(6):1113-21.
14. Zhang Y, Cai Y, Shi M, Jiang S, Cui S, Wu Y et al. The Prevalence of Vitiligo: A Meta-Analysis. PLoS One. 2016 Sep 27;11(9): e0163806.
15. Sisti A, Sisti G, Oranges CM. Effectiveness and safety of topical tacrolimus monotherapy for repigmentation in vitiligo: a comprehensive literature review. An Bras Dermatol. 2016 Apr;91(2):187-95.
16. González AP. Factores pronósticos en el vitiligo. Rev Cubana Invest Bioméd. 2014;33(3): 289-293.
17. Arýcan O, Koç K, Ersoy L. Clinical characteristics in 113 Turkish vitiligo patients. Acta Dermatovenerol Alp Pannonica Adriat. 2008 Sep;17(3):129-32.
18. Reghu R, James E. Epidemiological profile and treatment pattern of vitiligo in a tertiary care teaching hospital. Int J Pharm Sci. 2011;3:137–41.
19. Alikhan A, Felsten LM, Daly M, Petronic-Rosic V. Vitiligo: a comprehensive overview Part I. Introduction, epidemiology, quality of life, diagnosis, differential diagnosis, associations, histopathology, etiology, and work-up. J Am Acad Dermatol. 2011 Sep;65(3):473-91.
20. Silva, CMR, Pereira LB, Gontijo B, Ribeiro GB. Vitiligo na infância: características clínicas e epidemiológicas. An Bras Dermatol. 2007; (82):47-51.
21. Yaghoobi R, Omidian M, Bagherani N. Vitiligo: A review of the published work. J Dermatol. 2011 May;38(5):419-31.
22. Ezzedine K, Eleftheriadou V, Whitton M, van Geel N. Vitiligo. Lancet. 2015 Jul 4;386(9988):74-84.
23. Nanette BS. Pediatric Vitiligo. Pediatr Clin N Am. 2014;61: 347–66.
24. Sori T, Nath AK, Thappa DM, Jaisankar TJ. Hypopigmentary disorders in children in South India. Indian J Dermatol. 2011 Sep-Oct;56(5):546-9.
25. Santander MAS. Análisis del perfil de expresión de pacientes com vitiligo [thesis]. Nuevo Léon (MX): Facultad de Medicina de la Universidad Autónoma de Nuevo León;2012.
26. Al-Mutairi N, Sharma AK, Al-Sheltawy M, Nour-Eldin O. Childhood vitiligo: a prospective hospital-based study. Australas J Dermatol. 2005 Aug;46(3):150-3.
27. Campoverde TCS. Comportamiento clínico y manejo terapéutico del Vitiligo en los pacientes que acuden a consulta externa del Hospital Manuel Ygnacio Monteros Valdivieso, del IESS Loja. Del 1 de febrero del 2011 al 1 de febrero del 2012 [thesis]. Loja (EC): Universidad Nacional De Loja; 2012.
28. Farajzadeh S, Aflatoonian M, Mohammadi S, Vares B, Amiri R. Epidemiological aspects and disease association of childhood vitiligo. Journal of Pakistan Association of Dermatologists 2015 Mar;15 (2):105-110.
29. Schwartz, RA.; Janniger, CK. Vitiligo. Cutis. 1997 Nov;60(5):239-44.
30. Shah H, Mehta A, Astik B. Clinical and sociodemographic study of vitiligo. Indian J Dermatol Venereol Leprol. 2008 Nov-Dec;74(6):701.
31. Cavalcante MLLL, Pinto ACVD, Brito FF, Silva GV, Itimura G, Martelli,ACC. Perfil clínico e epidemiológico do vitiligo infantil: análise de 113 casos diagnosticados em um centro de referência em dermatologia de 2004 a 2014. Surg Cosmet Dermatol. 2015 Nov;7(4):298-301.
32. Ben Ahmed M, Zaraa I, Rekik R, Elbeldi-Ferchiou A, Kourda N, Belhadj Hmida N et al. Functional defects of peripheral regulatory T lymphocytes in patients with progressive vitiligo. Pigment Cell Melanoma Res. 2012 Jan;25(1): 99-109.
33. Correia KML, Borloti E. Convivendo com o vitiligo: uma análise descritiva da realidade vivida pelos portadores. Acta Comportamentalia. 2013 Jul; 21(2): 227-40.
34. Castro CCS. Prevalence of psoriasis in a study of 261 patients with vitiligo. An Bras Dermatol. 2005 Jul; 80(5):489-92.
35. Korobko IV, Lomonosov MK. Acridone acetic acid, sodium salt, as an agent to stop vitiligo progression: a pilot study. Dermatol Ther. 2014 Jul-Aug;27(4):219-22.
36. Manga P, Elbuluk N, Orlow SJ. Recent advances in understanding vitiligo. F1000Res. 2016 Sep; 5.
37. Noh S, Kim M, Parque CO, Hann SK, Oh SH. Comparison of the psychologics impacts os assimptomatic and symptomatic cutaneous diseases: vitiligo and atopic dermatitis. Ann dermatol. 2013 Nov;25(4):454-61.
38. Gönül M, Cakmak SK, Oğuz D, Gül U, Kiliç S. Profile of vitiligo patients attending a training and research hospital in Central Anatolia: A retrospective study. J Dermatol. 2012 Feb;39(2):156-9.
39. Ezzedine K, Silverberg N. A Practical Approach to the Diagnosis and Treatment of Vitiligo in Children. Pediatrics. 2016 Jul;138(1).
40. Gan EY, Gahat T, Cario-André M, Seneschal J, Ezzedine K, Taïeb A. Clinical repigmentation patterns in paediatric vitiligo. Br J Dermatol. 2016 Sep;175(3):555-60.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright policies & self-archiving
We are a RoMEO green journal.
Author's Pre-print: author can archive pre-print (ie pre-refereeing)
Author's Post-print: author can archive post-print (ie final draft post-refereeing)
Publisher's Version/PDF: author can archive publisher's version/PDF
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access and Benefits of Publishing Open Access).
This journal provides immediate open access to its content on the principle that making research freely available to the public supports a greater global exchange of knowledge.
Articles are published Under License of Creative Commons Attribution 4.0 License ©